Kikuchi Hirotoshi, Isshi Kunio, Hirohata Shunsei
Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo 173-8605, Japan.
Int Immunopharmacol. 2004 Jan;4(1):119-26. doi: 10.1016/j.intimp.2003.11.002.
Bucillamine (BUC) has been found to have beneficial effects in the treatment of rheumatoid arthritis (RA), in which the activation of endothelial cells plays an important role in the pathogenesis. The current studies examined the effect of BUC and its intramolecular disulfide form (BUC-ID) on the expression of adhesion molecules in human umbilical vein endothelial cells (HUVEC) stimulated with tumor necrosis factor-alpha (TNF-alpha). HUVEC (4 x 10(4)/well) were incubated with medium M199 containing heparin and 20% FCS with endothelial cell growth supplement (ECGS) for 24 h in the presence or absence of BUC or BUC-ID, after which the culture medium was replaced with ECGS free medium. Then the cultures were further carried out for additional 24 h with TNF-alpha (10 ng/ml) in the presence or absence of BUC or BUC-ID. BUC-ID, but not BUC, appeared to suppress the expression of VCAM-1 on HUVEC stimulated with TNF-alpha in a dose-response manner at its pharmacologically relevant concentrations (0.3-3.0 microg/ml), whereas only the 3 microg/ml concentration level of BUC-ID had a statistically significant effect, although the effect was relatively small. By contrast, lower concentrations of BUC-ID (1-3 microg/ml) suppressed the secretion of soluble VCAM-1 by HUVEC much more effectively. Of note, at the concentration of 3 microg/ml neither BUC nor BUC-ID significantly influenced the expression of ICAM-1 and E-selectin on TNF-alpha stimulated HUVEC. These results indicate that BUC-ID, but not BUC, specifically downregulates the surface expression of VCAM-1 as well as the release of soluble VCAM-1 by HUVEC stimulated with TNF-alpha. BUC-ID suppressed the production of solubleVCAM-1 by RA bone marrow CD34+ cells stimulated with SCF, GM-CSF and TNF-alpha more effectively than BUC. The data thus suggest that one of the mechanisms of action of BUC involves the inhibition of the activation of endothelial cells.
已发现布西拉明(BUC)在类风湿性关节炎(RA)治疗中具有有益作用,其中内皮细胞的激活在发病机制中起重要作用。当前研究检测了BUC及其分子内二硫键形式(BUC-ID)对经肿瘤坏死因子-α(TNF-α)刺激的人脐静脉内皮细胞(HUVEC)中黏附分子表达的影响。将HUVEC(4×10⁴/孔)在含有肝素、20%胎牛血清和内皮细胞生长补充剂(ECGS)的M199培养基中,于有或无BUC或BUC-ID的情况下孵育24小时,之后将培养基换成不含ECGS的培养基。然后在有或无BUC或BUC-ID的情况下,用TNF-α(10 ng/ml)将培养物再进一步培养24小时。在其药理学相关浓度(0.3 - 3.0微克/毫升)下,BUC-ID而非BUC似乎以剂量反应方式抑制经TNF-α刺激的HUVEC上VCAM-1的表达,尽管该作用相对较小,但仅3微克/毫升浓度水平的BUC-ID具有统计学显著效应。相比之下,较低浓度的BUC-ID(1 - 3微克/毫升)更有效地抑制HUVEC分泌可溶性VCAM-1。值得注意的是,在3微克/毫升浓度下,BUC和BUC-ID均未显著影响经TNF-α刺激的HUVEC上ICAM-1和E-选择素的表达。这些结果表明,BUC-ID而非BUC特异性下调经TNF-α刺激的HUVEC上VCAM-1的表面表达以及可溶性VCAM-1的释放。BUC-ID比BUC更有效地抑制经干细胞因子(SCF)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)和TNF-α刺激的RA骨髓CD34⁺细胞产生可溶性VCAM-1。因此,数据表明BUC的作用机制之一涉及抑制内皮细胞的激活。